Seleniso (Silvio) specifications and active ingredient content of each tablet

Selinexor (trade name: Xpovio) is an oral small molecule targeted drug developed by Karyopharm Therapeutics. It is mainly used to treat relapsed or refractory multiple myeloma and some refractory lymphomas. It is a selective nuclear export inhibitor (XPO1 inhibitor). By blocking the transport of key proteins in tumor cells, it inhibits cancer cell proliferation and induces apoptosis, providing a new treatment option for relapsed and refractory patients.

Currently, selinesol is only available in the market 20mg oral tablets. Tablets are round or oval in shape and are marked with dose markings on the surface for easy identification by patients and prescribing by doctors. A single specification allows doctors to achieve personalized treatment by adjusting the number of tablets and medication frequency according to the patient's weight, condition and tolerance.

Each selinesol tablet contains 20mg of active ingredient. The instructions emphasize that the tablet should be taken orally as a whole and should not be broken or chewed to ensure drug absorption and stable efficacy. Patients can take one or more tablets at a time according to the physician's instructions, and use them with an appropriate amount of water or food to reduce gastrointestinal discomfort and improve tolerance.

In clinical practice, selinesol is often used in combination with dexamethasone (Dexamethasone) for patients with relapsed or refractory multiple myeloma. Physicians will flexibly adjust the daily dose and frequency of medication based on the patient's blood indicators, liver and kidney function, and adverse reactions. During the period of medication, patients should regularly review blood routine and biochemical indicators, and strictly follow the doctor's instructions to take medication to ensure the safety and efficacy of treatment.

Reference link:https://www.drugs.com